Scottish Medicines Consortium accepted Adalimumab (Humira) for adolescents that do not respond to other DMARDs
An excerpt from the Drug Advice issued by the Scottish Medicines Consortium on adalimumab (Humira): adalimumab (Humira) is accepted for restricted use in NHS Scotland, in combination with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis in adolescents aged 13-17 years who have an inadequate response to one or more disease-modifying anti-rheumatic drugs […]